
Scientific Reports, Год журнала: 2024, Номер 14(1)
Опубликована: Ноя. 3, 2024
Bladder cancer (BLCA), ranking as the tenth most prevalent malignancy globally, imposes a substantial public health and socio-economic challenge. Despite ongoing efforts by urologists to identify novel molecular subtypes treatment paradigms, intrinsic heterogeneity of BLCA continues obstruct efficacy current diagnostic therapeutic evaluations, leaving gap in comprehensive management BLCA. This necessitates an in-depth investigation into tumor microenvironment (TME) pivotal molecules like MFAP3L. Our research concentrated on MFAP3L, commencing with pan-cancer analysis its immune profile. We discovered that MFAP3L exhibits significant negative correlation numerous components markers BLCA, trend not observed other types. Within TCGA-BLCA cohort, patients were classified High-MFAP3L Low-MFAP3L groups according their transcript levels. exploration TME delved infiltration, subtype patterns, preferences within these groups. High expression was linked favorable prognoses, luminal subtypes, low inversely associated various characteristics. Additionally, high expressors exhibited diminished checkpoint levels, suggesting enhanced immunotherapy tolerance sensitivity oncogenic pathway targeting. Conversely, correlated poor outcomes, basal increased heightened gene mutation rates, alongside radiotherapy, EGFR-targeted treatments, immunotherapy. Hence, emerges critical yet underexplored offering insights status aiding subtyping decision-making.
Язык: Английский